Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.
As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.
Teva (NYSE: TEVA) posted its Q4 2025 Aide Memoire on the company's Investors page to help investors ahead of fourth-quarter results.
The Aide Memoire compiles previously disclosed public information, prior results, management commentary and select independent data. Q4 2025 results are scheduled for Wednesday, January 28, 2026 at 7:00 AM ET, followed by a conference call at 8:00 AM ET.
Teva (NYSE: TEVA) submitted a New Drug Application (NDA) to the FDA on December 9, 2025 for olanzapine extended-release injectable suspension (TEV-'749), an investigational once-monthly subcutaneous long-acting injectable (LAI) for adults with schizophrenia.
The NDA is supported by Phase 3 SOLARIS trial data, including Week 56 results that the company says met efficacy and safety endpoints and showed a profile consistent with oral olanzapine. The formulation uses SteadyTeq copolymer technology, proprietary to Medincell. Olanzapine LAI is not approved by any regulatory authority at this time.
Teva (NYSE: TEVA) announced that the European Commission granted marketing authorizations on Nov 25, 2025 for two denosumab biosimilars: PONLIMSI (biosimilar to Prolia) and DEGEVMA (biosimilar to Xgeva).
The approvals follow positive CHMP opinions and allow Teva to launch both products in key European markets in the coming months. Teva frames the authorizations as a milestone for its biosimilars portfolio and part of its Pivot to Growth strategy to broaden patient access to bone‑health biologics across Europe.
Teva (NYSE: TEVA) announced that Richard Francis, president and CEO, and other executive management will present at three investor conferences in early December 2025.
Schedule: Evercore Healthcare Conference on Dec 3, 2025 at 8:20 AM ET; Piper Sandler Healthcare Conference on Dec 3, 2025 at 11:00 AM ET; and Citi 2025 Global Healthcare Conference on Dec 4, 2025 at 10:30 AM ET. Live webcasts will be available via Teva’s Investor Relations website and archived within 24 hours after each live presentation.
Teva (NYSE:TEVA) launched Teva Rise, a global open innovation platform on Nov 19, 2025 to connect startups and tech companies with Teva business units across R&D, manufacturing, supply chain and commercial functions.
The program issues an open call for solutions to seven real-world challenges (human-predictive platforms, AI clinical-trial protocol design, long-acting injectable patient experience, tender value optimization, asset predictive maintenance, product quality & risk prediction, and resource allocation intelligence) and may pilot selected startups across Teva’s global ecosystem.
Teva said it will channel tens of millions of dollars into adopting these innovations as part of its Pivot to Growth strategy.
Teva (NYSE: TEVA) announced interim real-world results from Part B of the IMPACT-TD Registry (Nov 7, 2025) showing patient-reported benefits after three months on AUSTEDO or AUSTEDO XR for tardive dyskinesia (TD).
In 27 adults, participants reported meaningful improvements in speech/communication (77%), eating (75%), psychosocial impact (65%), activities of daily living (59%), and sleep/pain (50%). The Abnormal Involuntary Movement Scale (AIMS) total motor score fell by a mean of -2.9. Among those taking concomitant mental health meds, 85% reported stable or improved mental health.
Teva (NYSE: TEVA) reported Q3 2025 revenues of $4.5 billion, marking the 11th consecutive quarter of growth. Key innovative brands grew 33% YoY in local currency to $830 million, led by AUSTEDO $618M (+38% LC), and Teva raised AUSTEDO's 2025 outlook to $2,050M–$2,150M. Q3 non-GAAP operating margin was 28.9% (+86 bps YoY), with a target of 30% by 2027. Q3 GAAP EPS was $0.37 and non-GAAP EPS $0.78. Free cash flow was $515M. Updated 2025 outlook: revenues $16.8B–$17.0B, non-GAAP EPS $2.55–$2.65.
Teva (NYSE:TEVA) launched a public education campaign called “The Other TD” on November 3, 2025 to raise awareness of tardive dyskinesia (TD) and encourage conversations with healthcare providers.
The campaign, supported by Pro Football Hall of Famer Terrell Davis, highlights that TD affects about 25% of people taking certain mental health medications and that an estimated 785,000 Americans may have TD while only ~15% receive a formal diagnosis and ~5% receive treatment. Materials cover symptom recognition, functional and social impact, treatment options that do not interrupt mental health care, and resources for care partners. Visit TheOtherTD.com for more information.
Teva (NYSE: TEVA) said Richard Francis, Teva's President and CEO, will present at two investor conferences in November 2025: UBS Global Healthcare Conference on Monday, November 10, 2025 at 8:45 AM ET and Jefferies London Healthcare Conference on Tuesday, November 18, 2025 at 11:00 AM GMT (6:00 AM ET).
Live webcasts will be available on Teva’s Investor Relations website and archived within 24 hours after each presentation.
Teva (NYSE: TEVA) entered a license and supply agreement with Prestige Biopharma to commercialize Tuznue® (trastuzumab), a biosimilar to Herceptin®, across a majority of European markets.
Tuznue® is approved for breast cancer and metastatic gastric cancer and received European Commission marketing authorization in September 2024. Under the deal, Prestige will produce and supply Tuznue® from its EU‑GMP, single‑use facilities while Teva will market and distribute using its European biosimilars commercial network.